Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal diseases, with an
average 5-year survival rate of less than 10%. Unfortunately, the majority of patients have …

Pancreatic ductal adenocarcinoma (PDAC), commonly referred to as pancreatic cancer,
ranks among the leading causes of cancer-related deaths in the Western world due to …

Background Pancreatic cancer continues to be one of the world's most lethal cancers.
Chemotherapy resistance in patients with advanced pancreatic cancer often accompany …

FBW7 functions as a tumor suppressor by targeting oncoproteins for degradation. Our
previous study found FBW7 was low expressed in pancreatic cancer due to sustained …

Ferroptosis is a new form of regulated cell death that is mediated by intracellular iron and
ester oxygenase, and glutathione-dependent lipid hydroperoxidase glutathione peroxidase …

Drug resistance is a major challenge in cancer treatment. Emerging evidence indicates that
deregulation of YAP/TAZ signaling may be a major mechanism of intrinsic and acquired …

Pancreatic ductal adenocarcinoma (PDAC) is known for its resistance to gemcitabine, which
acts to inhibit cell growth by termination of DNA replication. Tumor-associated macrophages …

Background Although gemcitabine has been considered as the first-line drug for advanced
pancreatic cancer (PC), development of resistance to gemcitabine severely limits the …

Gemcitabine (GEM) resistance is a major challenge for chemotherapy of pancreatic cancer.
Previous studies have reported on the role of long noncoding RNA (lncRNA) in …

Pancreatic ductal adenocarcinoma (PDA) is a lethal disease with limited response to
cytotoxic chemoradiotherapy, as well as newer immunotherapies. The PDA tumor …